Type 1 Diabetes Clinical Trials in Gainesville, Florida

6 studies are recruiting for type 1 diabetes in Gainesville, Florida right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)

   This study is a Phase 1b/2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-103. The approximately 393-days study consists of a Screening Period (28 days), Treatment Period (90 days), and Post-Dose Evalua…

   Stage

   Phase 1

   Ages

   12 to 35

   Site

   University of Florida, Gainesville, Florida

   Locations

   45 in total

   Run by

   COUR Pharmaceutical Development Company, Inc.

   See if you can join NCT06783309 on ClinicalTrials.gov

2. A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes

   This multi-center randomized controlled trial will assess the safety and efficacy of ATG followed by either adalimumab or verapamil in preserving insulin secretion 2 years from randomization in persons aged 9 to <21 with recent-onset stage 3 T1D.

   Stage

   Phase 1

   Ages

   9 to 20

   Site

   University of Florida, Gainesville, Florida

   Locations

   10 in total

   Run by

   City of Hope Medical Center

   See if you can join NCT07061574 on ClinicalTrials.gov

3. SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes

   This is a Phase 2b, investigator- and participant-blinded, placebo-controlled, parallel-arm study to evaluate the efficacy, safety and tolerability of SAB 142 in patients with Stage 3 New Onset of Type 1 Diabetes (NOT1D).

   Stage

   Phase 2

   Ages

   5 to 40

   Site

   University of Florida College of Medicine, Gainesville, Florida

   Locations

   70 in total

   Run by

   SAb Biotherapeutics, Inc.

   See if you can join NCT07187531 on ClinicalTrials.gov

4. Registry for Stage 2 Type 1 Diabetes

   Stage 2 Type 1 Diabates (T1D) is an early stage of T1D characterized by dysglycemia but not yet leading to clinical symptoms. Progression of the disease to Stage 3 (clinical T1D), leads to overt hyperglycemia requiring eventually exogenous insulin. TZIELD® (teplizumab-mzwv) has been approved to del…

   Stage

   Not phased

   Ages

   Any age

   Site

   University of Florida Health- Site Number : 8400035, Gainesville, Florida

   Locations

   37 in total

   Run by

   Sanofi

   See if you can join NCT06481904 on ClinicalTrials.gov

5. Immune Function and the Progression to T1D

   To elucidate the mechanisms by which type 1 diabetes-associated genes; IFIH1, TYK2, IKZF4, as well as total genetic risk, impart functional immunoregulatory abnormalities that result in expansion of self-reactive adaptive immune cells, defective regulatory/effector mechanisms in T cells, inflammato…

   Stage

   Not phased

   Ages

   0 to 100

   Site

   Kieran McGrail, Gainesville, Florida

   Locations

   3 in total

   Run by

   University of Florida

   See if you can join NCT05899439 on ClinicalTrials.gov

6. Precision Administration of Anti-thymocyte Globulin With or Without Verapamil

   T cell directed therapy, anti-thymocyte globulin (ATG), in low doses, has been shown to lower HbA1c and preserve endogenous insulin production (measured by C-peptide) in individuals with recently diagnosed type 1 diabetes (T1D). However, not all individuals who received ATG responded to the therapy…

   Stage

   Phase 2

   Ages

   6 to 35

   Site

   University of Florida, Gainesville, Florida

   Locations

   2 in total

   Run by

   University of Florida

   See if you can join NCT06455319 on ClinicalTrials.gov